Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    Authors: Hooman D Poor; Corey E. Ventetuolo; Thomas Tolbert; Glen Chun; Gregory Serrao; Amanda Zeidman; Neha S. Dangayach; Jeffrey Olin; Roopa Kohli-Seth; Charles A. Powell

    doi:10.1101/2020.04.17.20057125 Date: 2020-04-21 Source: medRxiv

    Patients with severe COVID-19 disease have been characterized as having the acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD). Critically ill MESHD COVID-19 patients have relatively well-preserved lung mechanics despite severe gas exchange abnormalities MESHD, a feature not consistent with classical ARDS but more consistent with pulmonary vascular disease MESHD. Patients with severe COVID-19 also demonstrate markedly abnormal coagulation MESHD, with elevated D-dimers and higher rates of venous thromboembolism MESHD thromboembolism HP. We present five cases of patients with severe COVID-19 pneumonia HP pneumonia MESHD with severe respiratory failure HP respiratory failure MESHD and shock HP, with evidence of markedly elevated dead-space ventilation who received tPA. All showed post treatment immediate improvements in gas exchange and/or hemodynamics. We suspect that severe COVID-19 pneumonia HP pneumonia MESHD causes respiratory failure HP respiratory failure MESHD via pulmonary microthrombi and endothelial dysfunction. Treatment for COVID-19 pneumonia HP pneumonia MESHD may warrant anticoagulation for milder cases and thrombolysis for more severe disease.

    Risk assessment of venous thromboembolism MESHD thromboembolism HP and bleeding MESHD in COVID-19 patients

    Authors: Jin-fu Xu; Lan Wang; Lan Zhao; Feng Li; Ji Liu; Li Zhang; Qiuhong Li; Jin Gu; Suo Liang; Qinhua Zhao; Jinmin Liu

    doi:10.21203/rs.3.rs-18340/v1 Date: 2020-03-20 Source: ResearchSquare

    Background The coronavirus disease MESHD 2019 (COVID-19) is a newly recognized illness that has spread rapidly all over the world. Severe hypoxemic respiratory failure MESHD respiratory failure HP from COVID-19 will bring high risk of venous thromboembolism MESHD thromboembolism HP ( VTE MESHD). Our study aims to identify in-hospital VTE MESHD risk and bleeding risk in COVID-19 patients. Methods We retrospectively studied 138 consecutively enrolled patients with COVID-19 and identified in-hospital VTE MESHD and bleeding risk by Padua Prediction Score and Improve bleed risk assessment model. The clinical data and features were analyzed in VTE MESHD patients. Results Our findings identified that 23 (16.67%) patients with COVID-19 were at high risk for VTE MESHD according to Padua prediction score, and 9(6.52%) patients were at high risk of bleeding MESHD for VTE MESHD prophylaxis according to Improve prediction score. Fifteen critically ill MESHD patients faced double high risk from thrombosis MESHD (Padua score more than 4 points in all 15[100%] patients) and hemorrhage MESHD (Improve score more than 7 points in 9[60.0%] patients). Thrombotic MESHD events were identified in four patients (2.9%) of all COVID-19 patients. All of them were diagnosed as deep vein thrombosis MESHD by ultrasound after 3 to 18 days after admission. Three (75.0%) were critically ill patients, which means the incidence of VTE MESHD among critically ill patients was 20%. One major hemorrhage MESHD was happened in critically ill MESHD patients during VTE MESHD treatment. Conclusion Critically ill MESHD patients with COVID-19 suffered both high risk of thrombosis MESHD and bleeding MESHD risks. More effective VTE MESHD prevention strategies based on an individual assessment of bleeding risks were necessary for critically ill patients with COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.